Antifungal activity of 6-substituted amiloride and hexamethylene amiloride (HMA) analogs

Fungal infections have become an increasing threat as a result of growing numbers of susceptible hosts and diminishing effectiveness of antifungal drugs due to multi-drug resistance. This reality underscores the need to develop novel drugs with unique mechanisms of action. We recently identified 5-(N,N-hexamethylene)amiloride (HMA), an inhibitor of human Na+/H+ exchanger isoform 1, as a promising scaffold for antifungal drug development. In this work, we carried out susceptibility testing of 45 6-substituted HMA and amiloride analogs against a panel of pathogenic fungi. A series of 6-(2-benzofuran)amiloride and HMA analogs that showed up to a 16-fold increase in activity against Cryptococcus neoformans were identified. Hits from these series showed broad-spectrum activity against both basidiomycete and ascomycete fungal pathogens, including multidrug-resistant clinical isolates.

[1]  M. Berney,et al.  An amiloride derivative is active against the F1Fo-ATP synthase and cytochrome bd oxidase of Mycobacterium tuberculosis , 2022, Communications Biology.

[2]  E. Blumwald,et al.  The Antifungal Activity of HMA, an Amiloride Analog and Inhibitor of Na+/H+ Exchangers , 2021, Frontiers in Microbiology.

[3]  David M. Shackleford,et al.  Systematic evaluation of structure-property relationships and pharmacokinetics in 6-(hetero)aryl-substituted matched pair analogs of amiloride and 5-(N,N-hexamethylene)amiloride. , 2021, Bioorganic & medicinal chemistry.

[4]  M. Ranson,et al.  Screening of 5- and 6-Substituted Amiloride Libraries Identifies Dual-uPA/NHE1 Active and Single Target-Selective Inhibitors , 2021, International journal of molecular sciences.

[5]  M. Friedman,et al.  Antifungal Drug Repurposing , 2020, Antibiotics.

[6]  Guanghua Huang,et al.  Candida auris: Epidemiology, biology, antifungal resistance, and virulence , 2020, PLoS pathogens.

[7]  A. Bonifaz,et al.  Antifungal Resistance in Candida auris: Molecular Determinants , 2020, Antibiotics.

[8]  J. Lopez-Ribot,et al.  Screening Repurposing Libraries for Identification of Drugs with Novel Antifungal Activity , 2020, Antimicrobial Agents and Chemotherapy.

[9]  F. Madeo,et al.  Fungal infections in humans: the silent crisis , 2020, Microbial cell.

[10]  Mingdong Huang,et al.  6-Substituted amiloride derivatives as inhibitors of the urokinase-type plasminogen activator for use in metastatic disease. , 2019, Bioorganic & medicinal chemistry letters.

[11]  J. Guarner,et al.  Emerging and reemerging fungal infections. , 2019, Seminars in diagnostic pathology.

[12]  Mingdong Huang,et al.  6-Substituted Hexamethylene Amiloride (HMA) Derivatives as Potent and Selective Inhibitors of the Human Urokinase Plasminogen Activator for Use in Cancer. , 2018, Journal of medicinal chemistry.

[13]  Y. Ota,et al.  Catheter-related bloodstream infection due to Rhodotorula mucilaginosa with normal serum (1→3)-β-D-glucan level. , 2018, Journal de mycologie medicale.

[14]  I. Falces-Romero,et al.  Isolation of Rhodotorula mucilaginosa from blood cultures in a tertiary care hospital , 2018, Mycoses.

[15]  M. Abassi,et al.  Emerging fluconazole resistance: Implications for the management of cryptococcal meningitis , 2017, Medical mycology case reports.

[16]  T. Sorrell,et al.  Candida and invasive mould diseases in non-neutropenic critically ill patients and patients with haematological cancer. , 2017, The Lancet. Infectious diseases.

[17]  A. Limper,et al.  Fungal infections in HIV/AIDS. , 2017, The Lancet. Infectious diseases.

[18]  Felix Bongomin,et al.  Global and Multi-National Prevalence of Fungal Diseases—Estimate Precision , 2017, Journal of fungi.

[19]  D. Boulware,et al.  Global burden of disease of HIV-associated cryptococcal meningitis: an updated analysis. , 2017, The Lancet. Infectious diseases.

[20]  C. Africa,et al.  Candida antifungal drug resistance in sub-Saharan African populations: A systematic review , 2016, F1000Research.

[21]  D. Boulware,et al.  Increased Antifungal Drug Resistance in Clinical Isolates of Cryptococcus neoformans in Uganda , 2015, Antimicrobial Agents and Chemotherapy.

[22]  George R Thompson,et al.  Coccidioidomycosis: epidemiology , 2013, Clinical epidemiology.

[23]  L. Goldani,et al.  Epidemiology of Rhodotorula: An Emerging Pathogen , 2012, Interdisciplinary perspectives on infectious diseases.

[24]  Mariana Henriques,et al.  Candida glabrata, Candida parapsilosis and Candida tropicalis: biology, epidemiology, pathogenicity and antifungal resistance. , 2012, FEMS microbiology reviews.

[25]  M. Ranson,et al.  Synthesis and preliminary evaluation of amiloride analogs as inhibitors of the urokinase-type plasminogen activator (uPA). , 2011, Bioorganic & medicinal chemistry letters.

[26]  M. Pfaller,et al.  Epidemiology of Invasive Mycoses in North America , 2010, Critical reviews in microbiology.

[27]  M. Burattini,et al.  Rhodotorula spp. isolated from blood cultures: clinical and microbiological aspects. , 2008, Medical mycology.

[28]  A. Casadevall,et al.  New insights on the pathogenesis of invasive Cryptococcus neoformans infection , 2007, Current infectious disease reports.

[29]  F. Tuon,et al.  Central venous catheter-associated fungemia due to Rhodotorula spp. --a systematic review. , 2007, Medical mycology.

[30]  M. Pfaller,et al.  Rare and Emerging Opportunistic Fungal Pathogens: Concern for Resistance beyond Candida albicans and Aspergillus fumigatus , 2004, Journal of Clinical Microbiology.

[31]  R. Wenzel,et al.  Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[32]  J. Heitman,et al.  Sexual Cycle of Cryptococcus neoformans var. grubii and Virulence of Congenic a and α Isolates , 2003, Infection and Immunity.

[33]  J. P. Woods.  Histoplasma capsulatum molecular genetics, pathogenesis, and responsiveness to its environment. , 2002, Fungal genetics and biology : FG & B.

[34]  D. Ellis,et al.  Ecology, life cycle, and infectious propagule of Cryptococcus neoformans , 1990, The Lancet.

[35]  E. Cragoe,et al.  Amiloride and its analogs as tools in the study of ion transport , 1988, The Journal of Membrane Biology.

[36]  A. Zuger,et al.  Cryptococcal disease in patients with the acquired immunodeficiency syndrome. Diagnostic features and outcome of treatment. , 1986, Annals of internal medicine.

[37]  D. Benos,et al.  Amiloride: a molecular probe of sodium transport in tissues and cells. , 1982, The American journal of physiology.

[38]  R. Humphries,et al.  Candida auris: An Emerging Yeast Pathogen Posing Distinct Challenges for Laboratory Diagnostics, Treatment, and Infection Prevention. , 2019, Archives of pathology & laboratory medicine.

[39]  C. Africa,et al.  Candida antifungal drug resistance in sub-Saharan African populations: A systematic review , 2016, F1000Research.

[40]  B. Lindemann,et al.  Structure-activity relationship of amiloride analogs as blockers of epithelial Na channels: I. Pyrazine-ring modifications , 2005, The Journal of Membrane Biology.

[41]  J. Heitman,et al.  Sexual cycle of Cryptococcus neoformans var. grubii and virulence of congenic a and alpha isolates. , 2003, Infection and immunity.